General Information of This Metabolic Reaction (MR) (ID: MR003018)
Formula
CYP3A4 ...
SVG example
O-demethylation
Reactant Erlotinib hydrochloride Product Erlotinib M14
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 3A4 (CYP3A4) DME Info
Cytochrome P450 3A5 (CYP3A5) DME Info
Cytochrome P450 1A1 (CYP1A1) DME Info
Cytochrome P450 1A2 (CYP1A2) DME Info
Metabolic Type Oxidation - O-demethylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003021 Erlotinib hydrochloride Erlotinib M11 Oxidation - Oxidation Erlotinib hydrochloride [1]
MR003005 Erlotinib hydrochloride Erlotinib M13 Oxidation - O-demethylation Erlotinib hydrochloride [1]
MR003013 Erlotinib hydrochloride Erlotinib M16 Unclear Erlotinib hydrochloride [1]
MR003019 Erlotinib hydrochloride Erlotinib M17 Unclear Erlotinib hydrochloride [1]
MR003020 Erlotinib hydrochloride Erlotinib M18 Oxidation - O-demethylation Erlotinib hydrochloride [1]
MR003022 Erlotinib hydrochloride Erlotinib M6 Oxidation - O-demethylation Erlotinib hydrochloride [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003007 Erlotinib M2 Erlotinib M14 Oxidation - O-demethylation Erlotinib hydrochloride [1], [2]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003008 Erlotinib M14 Erlotinib M10 Conjugation - O-glucuronidation Erlotinib hydrochloride [1]
MR003011 Erlotinib M14 Erlotinib M12 Conjugation - O-glucuronidation Erlotinib hydrochloride [1]
MR003009 Erlotinib M14 Erlotinib M17 Unclear Erlotinib hydrochloride [1]
MR003010 Erlotinib M14 Erlotinib M18 Conjugation - O-glucuronidation Erlotinib hydrochloride [1]
References
1 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
2 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.